Neuroplasticity in Psychiatry: The February 2026 Paradigm Shift

The Brain’s Capacity to Rewire Itself Takes Center Stage

The February 2026 issues of the American Psychiatric Association’s flagship journals have devoted substantial space to neuroplasticity mechanisms in mental illness—a convergence of research that signals psychiatry’s fundamental reconceptualization of how psychiatric disorders develop and how treatments work. Rather than viewing mental illness solely through the lens of chemical imbalances requiring symptomatic management, the field is increasingly embracing neuroplasticity as both the underlying pathology and the therapeutic target.

This shift represents more than academic theorizing. It carries profound implications for drug development, treatment selection, and patient outcomes across depression, schizophrenia, PTSD, addiction, and other high-burden psychiatric conditions.

What the Research Shows

The American Journal of Psychiatry’s February issue features a comprehensive review titled “Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments,” co-authored by leaders from Alto Neuroscience and former Janssen executives. The review consolidates extensive clinical and translational evidence demonstrating that disrupted neuroplasticity—spanning synaptic, cellular, and circuit-level dysfunction—serves as a shared biological driver across multiple psychiatric disorders.

The Core Argument: Neuroplasticity—the brain’s capacity to modify synaptic strength and connectivity—likely underlies both the pathophysiology of psychiatric disorders and the mechanisms through which treatments exert therapeutic effects. The review positions plasticity as measurable, druggable, and potentially causal, though the causality is likely bidirectional and disorder-specific. Rather than simple linear causation, plasticity deficits may both result from and contribute to psychiatric pathology, with the relationship varying across conditions like depression, schizophrenia, and bipolar disorder.

The evidence base is substantial. Studies show that chronic stress and depression are associated with neuronal atrophy and synaptic loss in the medial prefrontal cortex and hippocampus. Brain imaging reveals gray matter volume reductions in depression, particularly in the subgenual anterior cingulate cortex and hippocampus. Postmortem studies confirm actual loss of neurons and glia in chronic illness. These structural changes correlate with symptom severity and cognitive impairment.

Why This Framework Matters

Traditional psychiatric treatments were developed to provide symptomatic relief—SSRIs increase serotonin availability, and antipsychotics block dopamine receptors. The neuroplasticity framework suggests these medications work not through direct symptom suppression but by restoring the brain’s capacity to reorganize and adapt.

Consider the evidence:

• SSRIs promote cortical neuroplasticity through 5-HT7 receptor signaling that activates metalloproteinases mediating synapse formation
• Successful treatment with repetitive transcranial magnetic stimulation (rTMS) increases hippocampal volume, associated with cognitive improvement
• Ketamine induces rapid glutamatergic activity surges that trigger brain-derived neurotrophic factor (BDNF) release, forming new dendritic spines within hours

The review concludes that therapeutic efficacy across pharmacologic, neuromodulatory, and behavioral interventions consistently converges on restoration of neuroplasticity. This framework helps explain both treatment resistance (when plasticity cannot be restored) and durable clinical response (when circuit-level reorganization occurs).

The Clinical Implications

Rethinking Treatment Resistance

Approximately 30% of patients with major depression don’t respond adequately to first-line treatments. The neuroplasticity framework suggests these patients may have more profound plasticity deficits requiring different intervention strategies. Rather than simply trying more antidepressants at higher doses, clinicians might combine medications that enhance plasticity with behavioral therapies or brain stimulation that exercises new neural pathways.

Research on D-cycloserine—which enhances NMDA receptor function and promotes experience-dependent neuroplasticity—demonstrates this principle. When combined with exposure therapy for anxiety disorders, D-cycloserine doesn’t directly reduce anxiety but enhances the brain’s ability to learn new, non-fearful associations. The drug facilitates extinction learning, a fundamental plasticity process.

Personalized Treatment Selection

The neuroplasticity framework suggests that measuring a patient’s baseline plasticity capacity could guide treatment selection. Alto Neuroscience’s Precision Psychiatry Platform uses EEG activity, neurocognitive assessments, and wearable data to identify biomarkers predicting which patients will respond to which treatments. This represents a departure from trial-and-error prescribing toward biology-guided therapy selection.

The critical industry gap, as the AJP review notes, has been the historical absence of translatable biomarkers that directly index plasticity changes in humans. Animal models can measure dendritic spine density and synaptic protein levels, but clinical practice needs accessible biomarkers. Advances in functional neuroimaging, EEG analysis, and blood-based biomarkers (like BDNF levels) are beginning to fill this gap.

Combination Therapies

If treatments work by restoring neuroplasticity rather than directly suppressing symptoms, combining interventions that target plasticity through different mechanisms becomes rational. Early evidence supports this:

• SSRI combined with anodal transcranial direct current stimulation (tDCS) enhanced memory function better than either alone
• Ketamine may “kick-start” response to SSRIs by rapidly inducing plasticity that standard antidepressants can then maintain
• Cognitive behavioral therapy induces measurable changes in brain activity profiles, suggesting psychotherapy has neuroplastic underpinnings comparable to medications

The Novel Therapies Emerging

Digital Therapeutics

Rejoyn, recently FDA-approved for depression treatment, exemplifies neuroplasticity-based digital therapy. It’s an emotional face memory task patients complete on smartphones, designed to correct abnormal neural circuits through repeated engagement. Clinical trials showed efficacy comparable to some medications—achieved not through chemical intervention but by systematically retraining neural responses.

This represents a fundamentally different treatment paradigm: rather than compensating for dysfunctional circuits, the therapy aims to repair them through targeted cognitive exercise.

Rapid-Acting Interventions

Ketamine’s rapid antidepressant effects—improvements within hours rather than weeks—demonstrate that profound plasticity changes can occur quickly when the right mechanisms are engaged. This has catalyzed research into other rapid plasticity modulators, including psychedelics like psilocybin, which also show rapid onset effects through glutamatergic and serotonergic plasticity mechanisms.

Circuit-Based Treatments

Deep brain stimulation, transcranial magnetic stimulation, and magnetic seizure therapy induce plasticity by directly modulating neural circuit activity. These neuromodulation approaches are moving from last-resort treatments to earlier interventions as understanding of their plasticity-promoting mechanisms improves.

The Challenges Ahead

Biomarker Development

Clinical implementation requires practical biomarkers. Functional MRI provides rich data but is expensive and not widely accessible for routine treatment monitoring. Blood-based biomarkers like BDNF show promise but need validation across diverse patient populations and treatment types. EEG-based approaches offer good accessibility but require sophisticated analysis.

Treatment Duration

If the goal is inducing lasting plasticity changes rather than continuous symptom suppression, how long do treatments need to continue? The neuroplasticity framework suggests treatments might be discontinued once circuits reorganize, but determining when plasticity has been sufficiently restored remains unclear.

Individual Variability

Plasticity capacity varies with age, genetics, prior experiences, concurrent medical conditions, and other factors. Treatments effective at promoting plasticity in some patients may be insufficient in others. Personalization requires not just identifying which treatment but determining dosing, duration, and combination strategies for individual biology.

The Measurement Problem

How do we measure plasticity restoration in clinical practice? Gray matter volume changes on MRI? Cognitive test improvements? Symptom reduction? The field needs consensus on plasticity-relevant endpoints that are both meaningful and measurable.

***

The neuroplasticity paradigm doesn’t negate current treatments—SSRIs, antipsychotics, and mood stabilizers remain valuable. Rather, it reframes understanding of how they work and suggests strategies for optimization. It also opens pathways to novel interventions that more directly target plasticity mechanisms.

The February 2026 AJP focus on neuroplasticity signals growing consensus that this framework merits central position in psychiatric research and practice. Whether it delivers on its promise depends on translating mechanistic understanding into practical clinical tools—biomarkers that guide treatment selection, therapies that more efficiently restore plasticity, and combination approaches that address multiple plasticity deficits simultaneously.

For patients, this paradigm shift offers hope beyond symptom management: the possibility that treatments can fundamentally repair dysfunctional neural circuits rather than merely compensating for them. For clinicians, it provides biological rationale for treatment strategies previously based primarily on empirical observation.

The brain’s remarkable capacity to reorganize itself—once thought limited to childhood—represents psychiatry’s greatest therapeutic opportunity. The February 2026 research suggests the field is finally developing the tools to harness it.

If you enjoyed this piece, subscribe to our monthly newsletter to receive even more in-depth insights.

Sources

1. American Psychiatric Association. “February 2026 Issues of APA Journals Feature New Research on Neuroplasticity, Cannabis and Alcohol Use Interactions.” Press release, February 2, 2026. Available at: https://www.psychiatry.org/News-room/News-Releases/February-2026-Issues-of-APA-Journals
2. O’Donnell, P., Etkin, A., and Manji, H. “Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments.” American Journal of Psychiatry, Volume 183, Number 2, February 2026.
3. Alto Neuroscience. “Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment.” Business Wire, February 2026.
4. Price, R.B. and Duman, R. “Neuroplasticity in cognitive and psychological mechanisms of depression: An integrative model.” Molecular Psychiatry, 2020.
5. Krystal, J.H., et al. “Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy.” Biological Psychiatry, 62(8), 2007.
6. Singh, A. and Kar, S.K. “How electroconvulsive therapy works?: understanding the neurobiological mechanisms.” Clinical Psychopharmacology and Neuroscience, 15:210-21, 2017.
7. Pittenger, C. and Duman, R.S. “Stress, depression, and neuroplasticity: a convergence of mechanisms.” Neuropsychopharmacology, 33(1):88-109, 2008.
8. Kalin, N.H. “Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions.” American Journal of Psychiatry, 183(2):87-89, February 2026.
9. Psychiatric Times. “Digital Therapy Rejoyn Utilizes Neuroplasticity in Treating Depression.” February 5, 2026. Available at: https://www.psychiatrictimes.com/
10. Blumberger, D.M., et al. “Synaptic plasticity and mental health: methods, challenges and opportunities.” Neuropsychopharmacology, 2022.
11. Saha, R. “The Exciting Frontier of Neuroplasticity.” Journal of Behavioral and Brain Science, 2025.

Disclaimer: This article provides an analytical overview of neuroplasticity research published in February 2026 APA journals based on publicly available information. It is intended for educational purposes and does not constitute medical advice. Patients should consult qualified mental health professionals regarding treatment decisions. The field of neuroplasticity-based psychiatric treatment is rapidly evolving, and clinical applications remain under investigation.